Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following conferences in November and December 2022:
Related news for (CLSD)
- Biotech in Focus: Regulatory Wins, Strategic Moves, and Speculative Momentum
- Clearside Biomedical Secures Canadian Approval for XIPERE as Suprachoroidal Treatment for Uveitic Macular Edema
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/23/25 07:00 AM
- 24/7 Market News Snapshot 23 July, 2025 – Clearside Biomedical, Inc. Common Stock (NASDAQ:CLSD)
- Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada